Pneumonia: the impact of antibiotic resistance on its management

R G Finch1

  • 1Department of Microbiology and Infectious Diseases, City Hospital, Nottingham, U.K.

Microbial Drug Resistance (Larchmont, N.Y.)
|July 1, 1995
PubMed

Insights

Community-acquired pneumonia has diverse causes, with increasing antibiotic resistance in key pathogens like Streptococcus pneumoniae. Current guidelines recommend broad-spectrum antibiotics for severe cases and specific treatments for resistant strains.

Area of Science:

  • Infectious Diseases
  • Microbiology
  • Pulmonology

Background:

  • Community-acquired pneumonia (CAP) affects 1-5 per 1000 individuals annually, with varied microbial origins.
  • Predominant bacterial pathogens include pneumococci, Legionella spp., Mycoplasma pneumoniae, and Chlamydia pneumoniae.
  • Gram-negative enteric bacteria, though less common, present significant virulence and established antibiotic resistance.

Purpose of the Study:

  • To review the microbial etiology of CAP and the growing challenge of antibiotic resistance.
  • To compare and contrast current international consensus guidelines for CAP management.
  • To discuss optimal treatment strategies based on disease severity and pathogen resistance.

Main Methods:

  • Literature review of CAP etiology, focusing on predominant pathogens and resistance patterns.
  • Analysis of antibiotic resistance trends, particularly in Streptococcus pneumoniae and Haemophilus influenzae.
  • Comparison of treatment recommendations from major international respiratory societies and expert panels.

Main Results:

  • Antibiotic resistance is increasing in Streptococcus pneumoniae, a leading CAP pathogen, though clinical impact is still being established.
  • Haemophilus influenzae exhibits high levels of beta-lactamase production, necessitating beta-lactamase stable agents for severe pneumonia.
  • Macrolide and tetracycline resistance are more prevalent among pneumococci.

Conclusions:

  • Mild/moderate pneumococcal pneumonia may respond to high-dose amoxicillin or penicillin G if resistance is documented.
  • Severe CAP requires prompt, broad-spectrum empirical therapy to cover resistant pathogens and atypical infections.
  • Managing beta-lactam-allergic patients with multidrug-resistant pneumococcal disease poses a challenge, with glycopeptides as a preferred option.

Related Concept Videos

Pneumonia I: Introduction01:30

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Pneumonia V: Nursing management and Prevention01:30

Pneumonia V: Nursing management and Prevention

Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.
Mechanism of Antibiotic Resistance in MRSA01:25

Mechanism of Antibiotic Resistance in MRSA

Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and acquisition...
Pneumonia I: Introduction01:29

Pneumonia I: Introduction

Pneumonia is an infection of the lower respiratory tract that leads to inflammation of the lung parenchyma, often resulting in the accumulation of inflammatory exudate in the alveoli and airways. Unlike the watery, low-protein fluid exudate in pulmonary edema, the exudate in this case is a thick fluid rich in immune cells, proteins, and debris produced during infection and inflammation.This impairs gas exchange and can lead to consolidation of lung tissue. The infection may be caused by a...